Our Science

Develop stem cell treatments and restore liver health

Liver disease is estimated to cause 2 million deaths each year across the world¹. With incidence rising annually, the burden on health sciences and economies will also continue to increase.

our science

Whilst lifestyle adjustments such as a healthy diet and increased exercise are often enough to reverse the disease in its earlier stages, the signs of liver disease frequently go unnoticed until the disease has reached its later stages.

Patients that are unlucky enough to progress to late stage liver disease can develop acute-on-chronic liver failure (ACLF) and have a low chance of survival. Currently, the only way to save these patients’ lives is by replacing the damaged liver via transplantation.


Liver transplantations in the US in 2016².

13,705
Waiting list (WL)
7,841
Transplantations
6,743
Still alive 1 year after transplant
2,782
Removed from WL before transplantation
1,795
Died while waiting for a transplant

Promethera® aims to help patients in need of liver transplantation, by either finding a potential alternative to transplantation, or by providing more time for those to whom a transplant is essential by potentially stabilizing their disease progression.

Using intact, living cells in a therapeutic manner has an advantage over conventional pharmaceuticals since they can act as a cargo to provide multiple mechanisms in one treatment. This approach allows Promethera’s lead cell-therapy treatment, HepaStem®, to provide anti-fibrotic, anti-inflammatory and immunomodulatory benefits in one. Promethera® is therefore uniquely positioned among companies developing NASH treatments to develop a potential treatment for cirrhosis in late-stage NASH and ACLF.

A further benefit of Promethera®’s large experience in allogeneic approach is that multiple patients can be treated with one single donated liver or residual healthy liver tissue. The end result will be that patients can be offered a less invasive treatment option, as well as reducing demand for donated livers by ensuring each is used as efficiently as possible. 

References:

  1. Asrain SK et al. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171
  2. Global Observatory on Donation and Transplantation. Chart: Total liver. Accessed September 2019 via the GODT website